Antibodies
29 November 2016
FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma for Priority Review29 November 2016
Momenta Pharmaceuticals Announces Positive Top-Line Phase 3 Results for M923, a Proposed HUMIRA(R) (adalimumab) Biosimilar28 November 2016
MabVax Therapeutics Enrolls First Patients in Expansion of Phase I Clinical Trial Treating Newly Diagnosed Pancreatic Cancer Patients28 November 2016
Alder BioPharmaceuticals Initiates PROMISE 2 Pivotal Trial of Eptinezumab for the Prevention of Migraine22 November 2016
AstraZeneca head and neck cancer trials resume new patient enrolment as FDA lifts partial clinical hold19 November 2016
Innovative study with three treatment switches confirms Sandoz biosimilar etanercept has equivalent efficacy to originator17 November 2016
NW Bio Announces Phase II Clinical Trial Program Combining DCVax®-L and Pembrolizumab (Keytruda®) for Colorectal Cancer17 November 2016
Sanofi and Regeneron Announce Praluent® (alirocumab) Cardiovascular Outcomes Trial will Continue as Planned Following Interim Analysis17 November 2016
Amgen Announces Erenumab Significantly Reduces Monthly Migraine Days In Patients With Episodic Migraine In Second Phase 3 Study16 November 2016
Boehringer Ingelheim bevacizumab biosimilar candidate demonstrates bioequivalence to Avastin16 November 2016
Sanofi and Regeneron Present Results from Phase 3 MONARCH Study of Investigational Sarilumab at American College of Rheumatology Annual Meeting16 November 2016
Janssen Next-Generation Biologic Guselkumab Shows Promise In The Treatment Of Psoriatic Arthritis In Phase 2 Trial16 November 2016
Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 215 To U.S. Food And Drug Administration15 November 2016
New Phase 3 Data Show Simponi Aria® (Golimumab) Significantly Improved Signs And Symptoms In Patients With Active Ankylosing Spondylitis14 November 2016
Celldex Presents Data on New Product Candidate, CDX-1140, a Novel CD40 Agonist Antibody14 November 2016
Oncobiologics Announces Presentation of Final Data from Phase 1 Clinical Study of ONS-3010 (HUMIRA® Biosimilar)News Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports